Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples